ALDX Aldeyra Therapeutics

NASDAQ
$1.21

Aldeyra Therapeutics (ALDX) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -24.7% since its last earnings release on August 6, 2026.

Aldeyra Therapeutics Beat Consensus Estimates
Thursday, August 6, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · Before Open
Earnings Whisper
-
vs ($0.11)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.48

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Aldeyra Therapeutics

Aldeyra Therapeutics Inc is developing a treatment for diseases related to high levels of free aldehydes, naturally occurring pro-inflammatory toxins.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.